Iminophenimide is a piperazinedione derivative patented by American Cyanamid Co. as anticonvulsant.

Pildralazine is a hydralazinelike antihypertensive vasodilator containing a free hydrazine group. Potency of the compound was shown to be from 6 to 10 times greater than that of hydralazine although, from a qualitative point of view, the two drugs act similarly. Pildralazine was shown to be inactive on nictitating membrane contractions induced by sympathetic stimulation or by adrenaline injection into the lingual artery. However, it antagonized the vascular effects of adrenaline, angiotensin and vasopressin in pithed rats and spinal cats. Pildralazine significantly inhibited the onset of severe hypertension in rats; the combination of pildralazine with moderately effective doses of propranolol or dihydrochlorothiazide completely prevented the blood pressure increase. Whereas a lack of carcinogenic activity has been reported for pildralazine in 1983, a report published in Germany in 1985 states the drug to be mutagenic with auxotrophic mutants of S.Typhimurium and E.coli.

Almurtide (CGP 11637) is a synthetic muramyl dipeptide (MDP) analogue with potential immunostimulating and antineoplastic activity. As a derivative of the mycobacterial cell wall component MDP, almurtide activates both monocytes and macrophages. This results in the secretion of cytokines and induces the recruitment and activation of other immune cells, which may result in indirect tumoricidal or cytostatic effects. CGP 11637 has been shown to prevent oncogenic viral infections in mice.

Amipizone is an antithrombotic agent. It is antihypersensive and platelet-aggregation inhibitor. Amipizone is a pyridazinone that is active as cardiotonic agent.

Quisultazine is a phenothiazine derivative patented by MARPHA Societe d'Etude et d'Exploitation de Marques as pentagastrin antagonist. In preclinical studies, Quisultazine weakly inhibited pentagastrin-stimulated gastric secretion but was a powerful inhibitor of nocturnal gastric secretion. Quisultazine possesses a very weak affinity to muscarinic receptors in vitro and in vivo. It has negligible anticholinergic properties in rats and mice at the peripheral level but no effect at the central level.

Arbaclofen (STX209, R-baclofen), a selective agonist of GABA-B receptors, has been investigated in clinical trials for the treatment of autism spectrum disorder ASD, phase II and for the treatment of patients with fragile X syndrome in phase III. As a result, the drug did not meet the primary outcome of improved social avoidance in FXS in either study. In spite of positive results in some children with ASD, further study will be needed to replicate and extend these initial findings. Arbaclofen has also been investigated in phase III clinical trials as a treatment for spasticity due to multiple sclerosis.

Monatepil is a calcium antagonist that, as do existing calcium antagonists, inhibits the influx of extracellular Ca 2 + through voltage-dependent Ca 2 + channels. It is a new type of antihypertensive agent. Its unique chemical structure was specially designed with intrinsic calcium antagonist and a1 -adrenoceptor-blocking moieties, creating a dual mechanism of action. Positive effects on plasma lipid metabolism are derived from the a1 -adrenoceptor-blocking activity and the antiatherosclerotic effect derives from the calcium antagonist properties. The novel structure of monatepil produces a slow onset of action and a long-lasting antihypertensive effect in experimental animals.

Fenclexonium is an anticholinergic, spasmolytic agent.

Sulfachrysoidine is a sulfamylchrysoidine derivative and lipid-soluble azo dye with antibacterial activity.

Torcetrapib is a CETP inhibitor which was developed by Pfizer for the treatment of diseases associated with elevated level of cholesterol. The drug was tested in phase III (in combination with atorvastatin) of clinical trials in coronary heart disease patients as well as in patients with hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, however its development was terminated due to the high risk of death and heart problems.